WO1995001783A1 - New pharmaceutical formulation - Google Patents

New pharmaceutical formulation Download PDF

Info

Publication number
WO1995001783A1
WO1995001783A1 PCT/SE1994/000681 SE9400681W WO9501783A1 WO 1995001783 A1 WO1995001783 A1 WO 1995001783A1 SE 9400681 W SE9400681 W SE 9400681W WO 9501783 A1 WO9501783 A1 WO 9501783A1
Authority
WO
WIPO (PCT)
Prior art keywords
formulation according
omeprazole
core material
enteric coating
formulation
Prior art date
Application number
PCT/SE1994/000681
Other languages
French (fr)
Inventor
Inga Siv Bengtsson
Kurt Ingmar LÖVGREN
Original Assignee
Astra Aktiebolag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20390587&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1995001783(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to SK21-96A priority Critical patent/SK281105B6/en
Priority to AT94921155T priority patent/ATE231719T1/en
Priority to US08/313,036 priority patent/US5690960A/en
Priority to UA96010058A priority patent/UA43342C2/en
Priority to DK94921155T priority patent/DK0706378T3/en
Priority to SI9430438T priority patent/SI0706378T1/en
Priority to RU96102154/14A priority patent/RU2138254C9/en
Priority to DE69432076T priority patent/DE69432076T2/en
Priority to HU9503874A priority patent/HU226779B1/en
Priority to BR9406941A priority patent/BR9406941A/en
Priority to JP50400695A priority patent/JP3665334B2/en
Priority to KR1019960700052A priority patent/KR100350203B1/en
Priority to PL94312441A priority patent/PL175210B1/en
Priority to AU71982/94A priority patent/AU681686B2/en
Priority to EP94921155A priority patent/EP0706378B1/en
Application filed by Astra Aktiebolag filed Critical Astra Aktiebolag
Publication of WO1995001783A1 publication Critical patent/WO1995001783A1/en
Priority to NO19960067A priority patent/NO315146B1/en
Priority to FI960102A priority patent/FI114008B/en
Priority to HK98109229A priority patent/HK1008299A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Definitions

  • the present invention is related to a new pharmaceutical formulation containing a novel physical form of a magnesium salt of omeprazole, to a method for the manufacture of such a formulation, and to the use of such a formulation in medicine.
  • Omeprazole is useful for inhibiting gastric acid secretion and has gastric mucosa protective activity.
  • omeprazole may be used for prevention and treatment of gastric acid related disorders in mammals and man, including e.g. gastroesofageal reflux disease, gastritis, gastric ulcer and duodenal ulcer.
  • Omeprazole is susceptible to degradation/transformation in acid reacting and neutral media. The half-life of degradation of omeprazole in water solutions at pH- values less than four is shorter than ten minutes. Also at neutral pH-values degradation proceeds rapidly, e.g.
  • omeprazole also in the solid state is susceptible to degradation and is stabilized in mixtures with alkaline reacting compounds.
  • the stability of omeprazole is also affected by moisture, heat, organic solvents and to some degree by light.
  • omeprazole From what is said about the stability properties of omeprazole, it is obvious that an oral dosage form of omeprazole must be protected from contact with the acid reacting gastric juice and the active substance must be transferred in intact form to that part of the gastrointestinal tract where pH is near neutral and where rapid absorption of omeprazole can occur.
  • a pharmaceutical oral solid dosage form of omeprazole must be protected from contact with acidic gastric juice by an enteric coating.
  • an enteric coated omeprazole preparation containing a separating subcoat between the core material and the enteric coating. Said preparation contains an alkaline core comprising omeprazole, a subcoating and an enteric coating.
  • magnesium omeprazole in this specification denoted magnesium omeprazole, in full manufacturing scale in preparing pharmaceutical formulations primarily for oral administration, such as tablets, it is necessary that said magnesium omeprazole possesses a combination of properties which makes such full scale manufacturing feasible.
  • novel form of magnesium omeprazole can be formulated into different dosage forms for oral and rectal administration.
  • examples of such formulations are tablets, granules, pellets, capsules, suppositories and suspensions.
  • One object of the present invention is to provide a pharmaceutical formulation of magnesium omeprazole.
  • Another object of the present invention is to provide a process for full scale production of pharmaceutical formulations of omeprazole, especially an enteric coated dosage form of omeprazole, which is resistant to dissolution in acid media and which dissolves rapidly in neutral to alkaline media and has a good stability during long-term storage.
  • Yet another object of the invention is to provide an environmental friendly completely water-based process for the manufacture of pharmaceutical formulations of omeprazole.
  • the new dosage form is characterized in the following way.
  • Core material in the form of pellets, granules or tablets containing the novel form of a magnesium salt of omeprazole, optionally together with an alkaline reacting compound, and on said core material one or more subcoating layers optionally comprising tablet excipients which are soluble or insoluble but disintegrating in water, or polymeric, filmforming compounds, optionally containing pH-buffering, alkaline compounds between the core and an outer layer, which is an enteric coating.
  • This/these inner layer/layers separates/separate the core material from the outer layer being an enteric coating.
  • the process of forming the enteric coated dosage form is preferably water-based.
  • the enteric coating process step which usally is carried out using an organic solvent, can be carried out using a water-based process which is desirable both for the working environment inside the pharmaceutical plant and for global environmental reasons.
  • the new pharmaceutical formulation is defined in claims 1-8, a process for the manufacture of the pharmaceutical formulation according to the present invention is defined in claims 9-10 and the use of the formulation in medicine is defined in claims 11-17.
  • Magnesium omeprazole feasible for the manufacturing of the claimed formulation has the following properties:
  • a lower alcohol such as methanol, ethanol, n-propanol or iso-propanol, preferably methanol
  • a solution of polar solvents with a weighed amount of magnesium at temperatures between 0°C and reflux temperature.
  • the temperature should preferably be between 10 and 30°C.
  • the temperature can, in a second step be raised further to between 0°C and reflux temperature, preferably 20-50°C.
  • the temperature is reduced to 0-40°C, preferably 10-25°C.
  • Omeprazole or a salt of omeprazole is then added to the solution and after termination of the reaction the mixture is cooled to -10°C to +20°C, preferably -5°C to +5°C.
  • the solvent is then evaporated to 40-60% of the initial volume, which makes the inorganic salts precipitate.
  • T e precipitate is separated from the reaction solution for example by centrifugation or filtration and the solution is heated to 5°C to 30°C whereafter the solution is seeded with magnesium omeprazole crystals.
  • An amount of water, which is approximately equal to the volume of the solution, is added to start the crystallization.
  • the solution is cooled to -10 to +20°C, preferably 0-10°C to complete the crystallization.
  • the crystals are then separated from the mother liquid for example by centrifugation or filtration and washed with polar solvents preferably an aqueous lower alcohol such as aqueous methanol. Finally, the crystals are dried preferably under
  • novel magnesium salt of omeprazole herein referred to as magnesium omeprazole
  • inert preferably water soluble, conventional pharmaceutical constituents
  • the magnesium omeprazole may be mixed with an alkaline reacting, otherwise inert, pharmaceutically acceptable substance (or substances).
  • Such substances can be chosen among, but are not restricted to substances such as the sodium, potassium, calcium, magnesium and aluminium salts of phosphoric acid, carbonic acid, citric acid or other suitable weak inorganic or organic acids; aluminium hydroxide/sodium bicarbonate coprecipitate; substances normally used in antacid preparations such as aluminium, calcium and magnesium hydroxides; magnesium oxide or composite substances, such as Al 2 O3.6MgO.CO 2 .12H 2 O, (Mg 6 Al 2 (OH) 16 CO 3 .4H 2 O), MgO.Al 2 O 3 . 2Si ⁇ 2-nH2 ⁇ or similar compounds; organic pH-buffering substances such as trihydroxymethylaminomethane, basic amino acids and their salts or other similar, pharmaceutically acceptable pH-buffering substances.
  • substances such as the sodium, potassium, calcium, magnesium and aluminium salts of phosphoric acid, carbonic acid, citric acid or other suitable weak inorganic or organic acids; aluminium hydroxide/sodium bicarbonate copre
  • the powder mixture is then formulated into pellets, granules or tablets, by conventional pharmaceutical procedures.
  • the pellets, granules or tablets are used as core material for further processing.
  • the cores containing magnesium omeprazole and optionally alkaline reacting substances are separated from the enteric coating polymer(s).
  • the subcoating layer in the following defined as the separating layer, serves as a pH-buffering zone in which hydrogen ions diffusing from the outside in towards the core can react with hydroxyl ions diffusing from the core towards the surface of the coated particles.
  • the pH-buffering properties of the separating layer can be further strengthened by introducing in the layer substances chosen from a group of compounds usually used in antacid formulations such as, for instance, magnesium oxide, hydroxide or carbonate, aluminium or calcium hydroxide, carbonate or silicate; composite aluminium/magnesium compounds such as, for instance A 1 2 O 3 .6MgO.CO 2 .12H 2 O, (Mg 6 A 1 2 (OH) 16 CO 3 .4H 2 O), MgO.Al2O5.2SiO2.nH2O, aluminium hydroxide/sodium bicarbonate coprecipitate or similar compounds; or other pharmaceutically acceptable pH-buffering compounds such as, for instance the sodium, potassium, calcium, magnesium and aluminium salts of phosphoric, carbonic, citric or other suitable, weak, inorganic or organic acids; or suitable organic bases, including basic amino acids or salts thereof.
  • antacid formulations such as, for instance, magnesium oxide, hydroxide or carbonate, aluminium or
  • the separating layer may consist of one or more layers.
  • the separating layer(s) can be applied to the core material - pellets, granules or tablets - by conventional coating procedures in a suitable coating pan, centrifugal fluidized coating-granulator, or in a fluidized bed apparatus using water and/or conventional organic solvents for the coating solution.
  • the material for the separating layer is chosen among pharmaceutically acceptable, inert compounds or polymers used for film-coating applications such as, for instance, sugar, polyethylene glycol, polyvinylpyrrolidone, polyvinyl alcohol, hydroxypropyl cellulose, methylcellulose, ethylcellulose, hydroxymethyl cellulose or hydroxypropyl methylcellulose.
  • the separating layer, "subcoating", applied to the core material may constitute from approximately 0.5 to 25 % by weight of the core weight, preferably 2.0 - 10.0 %, and more preferably 2.5 - 5.0 %.
  • separating layer(s) In the case of a tablet formulation another method to apply the separating layer(s) can be performed by drycoating technique.
  • the separating layer(s) consists of pharmaceutically acceptable, soluble or insoluble but in water disintegrating tablet excipients.
  • the separating layer(s) has preferably a thickness of not less than approximately 1 mm.
  • ordinary plasticizers, colorants, pigments, titanium dioxide, talc and other additives may also be included into one or more of the separating layer(s).
  • Enteric coating layer may also be included into one or more of the separating layer(s).
  • the enteric coating layer is applied in one or more layers onto the subcoated core material by conventional coating techniques such as, for instance, pan coating or fluidized bed coating using solutions of polymers in water, or by using latex suspensions of said polymers or optionally using polymer solutions in suitable organic solvents.
  • enteric coating polymers can be used one or more of the following, for example solutions or dispersions of acrylates (methacrylic acid/methacrylic acid methylester copolymer), cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, polyvinyl acetate phthalate, cellulose acetate trimellitate, carboxymethylethylcellulose, shellac or other suitable enteric coating polymer(s).
  • acrylates methacrylic acid/methacrylic acid methylester copolymer
  • cellulose acetate phthalate hydroxypropyl methylcellulose phthalate
  • hydroxypropyl methylcellulose acetate succinate polyvinyl acetate phthalate
  • cellulose acetate trimellitate carboxymethylethylcellulose
  • shellac or other suitable enteric coating polymer(s).
  • enteric coating layer can optionally contain a pharmaceutically acceptable plasticizer for example cetanol, triacetin, citric acid es ⁇ ters such as, those known under the trade name Citroflex® (Pfizer), phthalic acid esters, dibutyl succinate, polyethylene glycol (PEG) or similar plasticizers.
  • a pharmaceutically acceptable plasticizer for example cetanol, triacetin, citric acid es ⁇ ters such as, those known under the trade name Citroflex® (Pfizer), phthalic acid esters, dibutyl succinate, polyethylene glycol (PEG) or similar plasticizers.
  • the amount of plasticizer is usually optimized for each enteric coating polymer(s) and is usually in the range of 1-50 % of the enteric coating polymer(s).
  • Dispersants such as talc, colorants and pigments may also be included into the enteric coating layer or sprayed onto the enteric coated material as an overcoat.
  • the thickness of the enteric coating may vary widely without influencing the in vitro release of omeprazole in test solutions which mimic in vivo conditions in man.
  • the enteric coating constitutes at least an amount of 1.0 % by weight of the core weight, preferably at least 3.0 % and especially at least 6.0 %.
  • the upper amount of the applied enteric coating is normally only limited by processing conditions. This possibility to vary the thickness of the enteric coating without deleterious influence on the release of omeprazole is especially desirable in large scale processes.
  • the enteric coating layer(s) may be applied on the pre-processed formulation containing subcoating layer(s) without exactly controlling the thickness of the applied coating layer(s).
  • the formulation according to the invention consists of core material containing magnesium omeprazole optionally mixed with alkaline reacting compound(s).
  • alkaline reacting material is not necessary, in any sense, but such a substance may further enhance the stability of omeprazole.
  • the core material is coated with an enteric coating rendering the dosage form insoluble in acid media, but disintegrating/dissolving in neutral to alkaline media such as, for instance the liquids present in the proximal part of the small intestine, the site where dissolution is wanted.
  • the core material is further coated with an soluble or insoluble but in water disintegrating coating, optionally containing one or more pH- buffering substances, which separate the core material from the enteric coating.
  • the final dosage form is either an enteric coated tablet or capsule or in the case of enteric coated pellets or granules, these pellets or granules dispensed in hard gelatin capsules or sachets.
  • the final dosage form may further be coated with an additional layer containing pigment(s) and/or colorant(s). It is essential for the long term stability during storage that the water content of the final dosage form containing magnesium omeprazole (enteric coated tablets, capsules, granules or pellets) is kept low.
  • a process for the manufacture of a dosage form according to the present invention represents a further aspect of the invention. After the forming of the core material, said material is first coated with the separating layer(s) and then with the enteric coating layer(s). The coating(s) are carried out as described above. Further another aspect of the invention is that the pharmaceutical processes can be completely water- based.
  • the preparation according to the invention is especially advantageous in reducing gastric acid secretion. It is administered one to several times a day.
  • the typical daily dose of the active substance varies and will depend on various factors such as the individual requirements of the patients, the mode of administration and the disease. In general the daily dose will be in the range of 1-400 mg of omeprazole.
  • Example 1 discloses the preparation of the novel magnesium omeprazole product, which product is suitable in manufacturing of the pharmaceutical formulations according to the present invention.
  • Example 2 discloses compositions of different enteric coated tablets containing magnesium omeprazole and results from acid resistance test and in vitro dissolution test.
  • Examples 3 discloses tablet formulations with different thickness of the enteric coating, the obtained gastric acid resistance of said formulations and the in vitro release rate of omeprazole.
  • Example 4 discloses an enteric coated pellet formulation.
  • Example 1 will serve to illustrate a process for manufacturing the magnesium omeprazole, which will be used in the pharmaceutical preparations according to the present invention.
  • a reactor was filled with 2026 litres of methanol. The stirrer was started and the temperature was adjusted to 20°C. 3,90 kg of magnesium was added to the vessel and immediately thereafter 1 ,0 litre of C ⁇ C ⁇ . The reactor was heated to 40°C and kept at this temperature for 60 min. It was then cooled to 15°C before the addition of 99,9 kg of omeprazole. The reactor was kept at this temperature for 60 min and then cooled to 0°C. The temperature was kept at this level for 30 minutes before 1000 L of methanol were evaporated under vacuum and the inorganic solid salt was separated from the liquid first by centrifugation and then by filtration.
  • the liquid was heated to 10°C and the liquid was seeded with magnesium omeprazole crystals whereafter the magnesium omeprazole salt was precipitated by addition of 900 L of water. The mixture was then cooled to 5°C. After the crystallization had been completed the magnesium omeprazole crystals were centrifuged off and then washed with a mixture of 50 L of methanol and 150 L of water. The produced magnesium omeprazole was dried under reduced pressure finally producing 92,5 kg of crystalline product corresponding to a yield of 81,4%.
  • the novel form of the magnesium salt of omeprazole according to Example 1 fulfills the properties defined above.
  • Methacrylic acid copolymer 9.1 9.1 9.1 Polyethylene glycol 1.0 1.0 1.0 Titanium dioxide 0.82 1.1 0.51 Colour iron oxide,red-brown 0.04 0.13 0.43 Colour iron oxide, yellow 0.02 - - Water purified 45.0 45.0 45.0
  • the tablets with an amount of 20 mg omeprazole/tablet have been manufactured both in a pilot scale of about 300 000 tablets and a large scale of about 2 million tablets.
  • Magnesium omeprazole, mannitol, hydroxypropyl methylcellulose, microcrystalline cellulose and sodium starch glycolate are dry-mixed, moistened with water and wet mixed. The wet mass is dried and milled and finally mixed with anti-adherent and lubricant substances. The milled granulate is compressed to tablets with a diameter of 7 mm. The tablets are sub-coated with a polymer film based on hydroxypropyl methylcellulose and enteric coated with a methacrylic acid copolymer film. Water used in the manufacture of the tablets is removed during subsequent processing. Investigation of acid-resistance
  • Tablet formulations containing magnesium omeprazole with different thickness of the enteric coating Tablet formulations containing magnesium omeprazole with different thickness of the enteric coating.
  • the composition of the tablets is the same as in Example 2 (20 mg omeprazole).
  • Enteric coated pellet formulation containing magnesium omeprazole Enteric coated pellet formulation containing magnesium omeprazole.
  • Methacrylic acid copolymer 430 g Polyethylene glycol 40 g
  • the dry ingredients given above were mixed well in a mixer. Addition of granulation liquid was made and the mixture was kneaded and granulated to a proper consistency. The wet mass was pressed through an extruder and the granules were converted to spherical form in a spheronizer. The pellets were dried and classified into suitable particle size ranges, e.g. 0.5-1.5 mm.
  • the polymer solution (I) was sprayed on the uncoated pellets in a fluidized bed apparatus under conditions suitable for the equipment used.
  • the polymer dispersion (II) was sprayed on the subcoated pellets in a fluidized bed apparatus.
  • the enteric -coated pellets were classified, polishing material was admixed and the pellets were filled into hard gelatin capsules in an amount co ⁇ esponding to 20 mg of omeprazole, using a capsule filling machine.
  • the enteric coated formulations according to Example 2 have been tested in humans with good results.

Abstract

A new oral pharmaceutical formulation containing a novel physical form of a magnesium salt of omeprazole, a method for the manufacture of such a formulation, and the use of such a formulation in medicine.

Description

NEW PHARMACEUTICAL FORMULATION
Field of the invention
The present invention is related to a new pharmaceutical formulation containing a novel physical form of a magnesium salt of omeprazole, to a method for the manufacture of such a formulation, and to the use of such a formulation in medicine.
Background of the invention
The compound known under the generic name omeprazole, 5-methoxy-2(((4- methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulflnyl)-lH-benzimidazole, is described i.a. in EP-A 0 005 129.
Omeprazole is useful for inhibiting gastric acid secretion and has gastric mucosa protective activity. In a more general sense, omeprazole may be used for prevention and treatment of gastric acid related disorders in mammals and man, including e.g. gastroesofageal reflux disease, gastritis, gastric ulcer and duodenal ulcer. Omeprazole is susceptible to degradation/transformation in acid reacting and neutral media. The half-life of degradation of omeprazole in water solutions at pH- values less than four is shorter than ten minutes. Also at neutral pH-values degradation proceeds rapidly, e.g. at pH=7 the half -life of omeprazole is about 14 hours, while at higher pH-values the stability in solution is much better (Pilbrant and Cederberg, Scand. J. Gastroenterology 1985; 20 (suppl. 108) p. 113-120). Omeprazole also in the solid state is susceptible to degradation and is stabilized in mixtures with alkaline reacting compounds. The stability of omeprazole is also affected by moisture, heat, organic solvents and to some degree by light. From what is said about the stability properties of omeprazole, it is obvious that an oral dosage form of omeprazole must be protected from contact with the acid reacting gastric juice and the active substance must be transferred in intact form to that part of the gastrointestinal tract where pH is near neutral and where rapid absorption of omeprazole can occur.
A pharmaceutical oral solid dosage form of omeprazole must be protected from contact with acidic gastric juice by an enteric coating. In US-A 4,786,505 is described an enteric coated omeprazole preparation containing a separating subcoat between the core material and the enteric coating. Said preparation contains an alkaline core comprising omeprazole, a subcoating and an enteric coating.
Certain salts of omeprazole including alkaline reacting salts of omeprazole are described in EP-A 0 124 495. In said patent specification the requirements and importance regarding storage stability of omeprazole for incorporation in pharmaceutical preparations are emphasized.
There is however, a demand for the development of new enteric preparations of omeprazole with enhanced stability and for environmental aspects there is also a strong desire for the use of water based processes in production of pharmaceutical products.
The isolation and purification in full manufacturing scale of the magnesium omeprazole salts described in EP-A 0 124 495 presents one major problem in that the magnesium omeprazole salt particles are very fragile making pharmaceutical manufacturing processes utilising this product less attractive in full scale production. Performing the process without crystallization of the magnesium omeprazole gives a product which is less suitable as a pharmaceutical substance.
In order to use the magnesium salt of omeprazole, in this specification denoted magnesium omeprazole, in full manufacturing scale in preparing pharmaceutical formulations primarily for oral administration, such as tablets, it is necessary that said magnesium omeprazole possesses a combination of properties which makes such full scale manufacturing feasible.
The combination of physical properties of the novel magnesium omeprazole product described in the present specification with respect to the degree of crystallinity, particle diameter, density, hygroscopicity, low water content and low content of other solvents is favorable and permits the manufacture of magnesium omeprazole in a form which is useful for the manufacture of the new pharmaceutical formulation.
The novel form of magnesium omeprazole can be formulated into different dosage forms for oral and rectal administration. Examples of such formulations are tablets, granules, pellets, capsules, suppositories and suspensions.
Description of the invention
One object of the present invention is to provide a pharmaceutical formulation of magnesium omeprazole.
Another object of the present invention is to provide a process for full scale production of pharmaceutical formulations of omeprazole, especially an enteric coated dosage form of omeprazole, which is resistant to dissolution in acid media and which dissolves rapidly in neutral to alkaline media and has a good stability during long-term storage.
Yet another object of the invention is to provide an environmental friendly completely water-based process for the manufacture of pharmaceutical formulations of omeprazole.
The new dosage form is characterized in the following way. Core material in the form of pellets, granules or tablets containing the novel form of a magnesium salt of omeprazole, optionally together with an alkaline reacting compound, and on said core material one or more subcoating layers optionally comprising tablet excipients which are soluble or insoluble but disintegrating in water, or polymeric, filmforming compounds, optionally containing pH-buffering, alkaline compounds between the core and an outer layer, which is an enteric coating. This/these inner layer/layers separates/separate the core material from the outer layer being an enteric coating.
The process of forming the enteric coated dosage form is preferably water-based. Also the enteric coating process step, which usally is carried out using an organic solvent, can be carried out using a water-based process which is desirable both for the working environment inside the pharmaceutical plant and for global environmental reasons.
It has been found that a magnesium omeprazole having a degree of crystallinity which is higher than 70% is useful in the manufacture of the pharmaceutical formulations of omeprazole according to the present invention.
Detailed description of the invention
The new pharmaceutical formulation is defined in claims 1-8, a process for the manufacture of the pharmaceutical formulation according to the present invention is defined in claims 9-10 and the use of the formulation in medicine is defined in claims 11-17.
Magnesium omeprazole
Magnesium omeprazole feasible for the manufacturing of the claimed formulation has the following properties:
a) Crystalline form, with a degree of crystallinity of not less than 70%, preferably higher than 75% as determined by X-ray powder diffraction It is desirable that the product also exhibits the following properties;
b) Particle size measured as mean mass diameter (MMD) less than
30 μm, preferably less than 20 μm as determined by laser diffraction technique.
c) Density between 1.33 g/cm 3 and 1.35 g cm 3 as determined by powder pycnometer.
d) Hygroscopicity not exceeding 2% increase of weight upon storage for one month up to 94% relative atmospheric humidity as determined gravimetrically.
e) A content of water of between 5% and 10% by weight as determined by titration according to Karl Fischer.
f) A content of methanol less than 0.1% preferably less than 0.05% by weight as determined by gas chromatography, in case methanol is used as solvent.
The process for producing the novel form of magnesium omeprazole is characterized by the following consecutive steps
1) treating omeprazole or a salt thereof with magnesium alcoholate in a solution
2) separating inorganic salts from the reaction mixture
3) crystallizing magnesium omeprazole
4) isolating the obtained crystalline magnesium omeprazole and, optionally
5) purifying and drying the crystalline magnesium omeprazole using conventional methods. The process for manufacturing the novel magnesium omeprazole can be described in the following way:
A lower alcohol, such as methanol, ethanol, n-propanol or iso-propanol, preferably methanol, is treated in a solution of polar solvents with a weighed amount of magnesium at temperatures between 0°C and reflux temperature. The temperature should preferably be between 10 and 30°C. After addition of the magnesium to the solution the temperature can, in a second step be raised further to between 0°C and reflux temperature, preferably 20-50°C. After termination of the reaction the temperature is reduced to 0-40°C, preferably 10-25°C. Omeprazole or a salt of omeprazole is then added to the solution and after termination of the reaction the mixture is cooled to -10°C to +20°C, preferably -5°C to +5°C. The solvent is then evaporated to 40-60% of the initial volume, which makes the inorganic salts precipitate. T e precipitate is separated from the reaction solution for example by centrifugation or filtration and the solution is heated to 5°C to 30°C whereafter the solution is seeded with magnesium omeprazole crystals. An amount of water, which is approximately equal to the volume of the solution, is added to start the crystallization. The solution is cooled to -10 to +20°C, preferably 0-10°C to complete the crystallization. The crystals are then separated from the mother liquid for example by centrifugation or filtration and washed with polar solvents preferably an aqueous lower alcohol such as aqueous methanol. Finally, the crystals are dried preferably under reduced pressure and heating.
Pharmaceutical formulations containing the novel magnesium omeprazole described above are manufactured as described herein below.
Core material
The novel magnesium salt of omeprazole, herein referred to as magnesium omeprazole, is mixed with inert, preferably water soluble, conventional pharmaceutical constituents to obtain the preferred concentration of omeprazole in the final mixture. Optionally the magnesium omeprazole may be mixed with an alkaline reacting, otherwise inert, pharmaceutically acceptable substance (or substances). Such substances can be chosen among, but are not restricted to substances such as the sodium, potassium, calcium, magnesium and aluminium salts of phosphoric acid, carbonic acid, citric acid or other suitable weak inorganic or organic acids; aluminium hydroxide/sodium bicarbonate coprecipitate; substances normally used in antacid preparations such as aluminium, calcium and magnesium hydroxides; magnesium oxide or composite substances, such as Al2O3.6MgO.CO2.12H2O, (Mg6Al2(OH)16CO3.4H2O), MgO.Al2O3. 2Siθ2-nH2θ or similar compounds; organic pH-buffering substances such as trihydroxymethylaminomethane, basic amino acids and their salts or other similar, pharmaceutically acceptable pH-buffering substances.
The powder mixture is then formulated into pellets, granules or tablets, by conventional pharmaceutical procedures. The pellets, granules or tablets are used as core material for further processing.
Separating layer - subcoating.
The cores containing magnesium omeprazole and optionally alkaline reacting substances are separated from the enteric coating polymer(s). The subcoating layer, in the following defined as the separating layer, serves as a pH-buffering zone in which hydrogen ions diffusing from the outside in towards the core can react with hydroxyl ions diffusing from the core towards the surface of the coated particles. The pH-buffering properties of the separating layer can be further strengthened by introducing in the layer substances chosen from a group of compounds usually used in antacid formulations such as, for instance, magnesium oxide, hydroxide or carbonate, aluminium or calcium hydroxide, carbonate or silicate; composite aluminium/magnesium compounds such as, for instance A 12O3.6MgO.CO2.12H2O, (Mg6 A 12(OH) 16CO3.4H2O), MgO.Al2O5.2SiO2.nH2O, aluminium hydroxide/sodium bicarbonate coprecipitate or similar compounds; or other pharmaceutically acceptable pH-buffering compounds such as, for instance the sodium, potassium, calcium, magnesium and aluminium salts of phosphoric, carbonic, citric or other suitable, weak, inorganic or organic acids; or suitable organic bases, including basic amino acids or salts thereof.
The separating layer may consist of one or more layers.
The separating layer(s) can be applied to the core material - pellets, granules or tablets - by conventional coating procedures in a suitable coating pan, centrifugal fluidized coating-granulator, or in a fluidized bed apparatus using water and/or conventional organic solvents for the coating solution. The material for the separating layer is chosen among pharmaceutically acceptable, inert compounds or polymers used for film-coating applications such as, for instance, sugar, polyethylene glycol, polyvinylpyrrolidone, polyvinyl alcohol, hydroxypropyl cellulose, methylcellulose, ethylcellulose, hydroxymethyl cellulose or hydroxypropyl methylcellulose. The separating layer, "subcoating", applied to the core material may constitute from approximately 0.5 to 25 % by weight of the core weight, preferably 2.0 - 10.0 %, and more preferably 2.5 - 5.0 %.
In the case of a tablet formulation another method to apply the separating layer(s) can be performed by drycoating technique. First a tablet containing magnesium omeprazole is formulated as described above. Around this tablet one or more layers are compressed using a suitable tableting machine. The separating layer(s) consists of pharmaceutically acceptable, soluble or insoluble but in water disintegrating tablet excipients. The separating layer(s) has preferably a thickness of not less than approximately 1 mm.
Ordinary plasticizers, colorants, pigments, titanium dioxide, talc and other additives may also be included into one or more of the separating layer(s). Enteric coating layer
The enteric coating layer is applied in one or more layers onto the subcoated core material by conventional coating techniques such as, for instance, pan coating or fluidized bed coating using solutions of polymers in water, or by using latex suspensions of said polymers or optionally using polymer solutions in suitable organic solvents. As enteric coating polymers can be used one or more of the following, for example solutions or dispersions of acrylates (methacrylic acid/methacrylic acid methylester copolymer), cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, polyvinyl acetate phthalate, cellulose acetate trimellitate, carboxymethylethylcellulose, shellac or other suitable enteric coating polymer(s). Preferably water-based polymer dispersions such as for example compounds known under the trade names Aquateric® (FMC Corporation), Eudragit® (Rohm Pharma), Aqoat (Shin-Etsu Chemical), Opadry (Colorcon) or similar compounds are used to obtain enteric coatings. The enteric coating layer can optionally contain a pharmaceutically acceptable plasticizer for example cetanol, triacetin, citric acid es¬ ters such as, those known under the trade name Citroflex® (Pfizer), phthalic acid esters, dibutyl succinate, polyethylene glycol (PEG) or similar plasticizers. The amount of plasticizer is usually optimized for each enteric coating polymer(s) and is usually in the range of 1-50 % of the enteric coating polymer(s). Dispersants such as talc, colorants and pigments may also be included into the enteric coating layer or sprayed onto the enteric coated material as an overcoat.
The thickness of the enteric coating may vary widely without influencing the in vitro release of omeprazole in test solutions which mimic in vivo conditions in man. To protect the acid susceptible omeprazole compound and to obtain an acceptable acid resistance, the enteric coating constitutes at least an amount of 1.0 % by weight of the core weight, preferably at least 3.0 % and especially at least 6.0 %. The upper amount of the applied enteric coating is normally only limited by processing conditions. This possibility to vary the thickness of the enteric coating without deleterious influence on the release of omeprazole is especially desirable in large scale processes. The enteric coating layer(s) may be applied on the pre-processed formulation containing subcoating layer(s) without exactly controlling the thickness of the applied coating layer(s).
Thus, the formulation according to the invention consists of core material containing magnesium omeprazole optionally mixed with alkaline reacting compound(s). The addition of alkaline reacting material is not necessary, in any sense, but such a substance may further enhance the stability of omeprazole. The core material is coated with an enteric coating rendering the dosage form insoluble in acid media, but disintegrating/dissolving in neutral to alkaline media such as, for instance the liquids present in the proximal part of the small intestine, the site where dissolution is wanted. The core material is further coated with an soluble or insoluble but in water disintegrating coating, optionally containing one or more pH- buffering substances, which separate the core material from the enteric coating.
Final dosage form
The final dosage form is either an enteric coated tablet or capsule or in the case of enteric coated pellets or granules, these pellets or granules dispensed in hard gelatin capsules or sachets. The final dosage form may further be coated with an additional layer containing pigment(s) and/or colorant(s). It is essential for the long term stability during storage that the water content of the final dosage form containing magnesium omeprazole (enteric coated tablets, capsules, granules or pellets) is kept low.
Process
A process for the manufacture of a dosage form according to the present invention represents a further aspect of the invention. After the forming of the core material, said material is first coated with the separating layer(s) and then with the enteric coating layer(s). The coating(s) are carried out as described above. Further another aspect of the invention is that the pharmaceutical processes can be completely water- based.
The preparation according to the invention is especially advantageous in reducing gastric acid secretion. It is administered one to several times a day. The typical daily dose of the active substance varies and will depend on various factors such as the individual requirements of the patients, the mode of administration and the disease. In general the daily dose will be in the range of 1-400 mg of omeprazole.
The invention is illustrated in detail by the following examples. Example 1 discloses the preparation of the novel magnesium omeprazole product, which product is suitable in manufacturing of the pharmaceutical formulations according to the present invention. Example 2 discloses compositions of different enteric coated tablets containing magnesium omeprazole and results from acid resistance test and in vitro dissolution test. Examples 3 discloses tablet formulations with different thickness of the enteric coating, the obtained gastric acid resistance of said formulations and the in vitro release rate of omeprazole. Example 4 discloses an enteric coated pellet formulation.
Examples
The following detailed Example 1 will serve to illustrate a process for manufacturing the magnesium omeprazole, which will be used in the pharmaceutical preparations according to the present invention.
Example 1
A reactor was filled with 2026 litres of methanol. The stirrer was started and the temperature was adjusted to 20°C. 3,90 kg of magnesium was added to the vessel and immediately thereafter 1 ,0 litre of C^C^. The reactor was heated to 40°C and kept at this temperature for 60 min. It was then cooled to 15°C before the addition of 99,9 kg of omeprazole. The reactor was kept at this temperature for 60 min and then cooled to 0°C. The temperature was kept at this level for 30 minutes before 1000 L of methanol were evaporated under vacuum and the inorganic solid salt was separated from the liquid first by centrifugation and then by filtration. The liquid was heated to 10°C and the liquid was seeded with magnesium omeprazole crystals whereafter the magnesium omeprazole salt was precipitated by addition of 900 L of water. The mixture was then cooled to 5°C. After the crystallization had been completed the magnesium omeprazole crystals were centrifuged off and then washed with a mixture of 50 L of methanol and 150 L of water. The produced magnesium omeprazole was dried under reduced pressure finally producing 92,5 kg of crystalline product corresponding to a yield of 81,4%.
The novel form of the magnesium salt of omeprazole according to Example 1 fulfills the properties defined above.
Example 2
Tablet formulations containing magnesium omeprazole.
Amount omeprazole 10 20 40 Ingredient (mg/tabl) (mg/tabl) (mg/tabl)
Tablet core
Magnesium omeprazole 11.2 22.5 45.0
Mannitol 68.7 57.4 34.9
Microcrystalline cellulose 25.0 25.0 25.0
Sodium starch glycolate 6.0 6.0 6.0
Hydroxypropyl methylcellulose 6.0 6.0 6.0
Talc 5.0 5.0 5.0
Sodium stearyl fumarate 2.5 2.5 2.5
Water purified 50.0 50.0 50.0 Sub-coating layer
Hydroxypropyl methylcellulose 3.7 3.7 3.7
Hydrogen peroxide 30% 0.04 0.04 0.04
Water purified 34.0 34.0 34.0
Enteric coating layer
Methacrylic acid copolymer 9.1 9.1 9.1 Polyethylene glycol 1.0 1.0 1.0 Titanium dioxide 0.82 1.1 0.51 Colour iron oxide,red-brown 0.04 0.13 0.43 Colour iron oxide, yellow 0.02 - - Water purified 45.0 45.0 45.0
Polish
Paraffin powder 0.05 0.05 0.05
The tablets with an amount of 20 mg omeprazole/tablet have been manufactured both in a pilot scale of about 300 000 tablets and a large scale of about 2 million tablets.
Description of manufacturing
Magnesium omeprazole, mannitol, hydroxypropyl methylcellulose, microcrystalline cellulose and sodium starch glycolate are dry-mixed, moistened with water and wet mixed. The wet mass is dried and milled and finally mixed with anti-adherent and lubricant substances. The milled granulate is compressed to tablets with a diameter of 7 mm. The tablets are sub-coated with a polymer film based on hydroxypropyl methylcellulose and enteric coated with a methacrylic acid copolymer film. Water used in the manufacture of the tablets is removed during subsequent processing. Investigation of acid-resistance
Six individual tablets were exposed to artificial gastric fluid without enzymes, pH 1.2. After six hours the tablets were removed, washed and analysed for omeprazole content using HPLC. The amount of omeprazole is taken as acid resistance.
Tablet Acid resistance
Strength
(mg) (%)
10 95 (93-98)
20 100 (94-102)
40 100 (96-103)
Investigation of in-vitro dissolution
After exposure to acid environment, pH 1.2, as described above, the medium was switched to artificial intestinal fluid without enzymes, pH 6.8. The dissolved amount of omeprazole was determined by HPLC.
Tablet Dissolved amount of omeprazole (%) after (minutes)
Strength 0 5 10 15 20 25 30
(mg) (%) (%) (%) (%) (%) (%) (%)
10 0 2 78 92 93 94 94 20 0 0 75 93 96 96 97 40 0 9 71 86 91 91 94
All values of dissolved amount of omeprazole are mean values of 12 tablets. Example 3
Tablet formulations containing magnesium omeprazole with different thickness of the enteric coating.
The composition of the tablets is the same as in Example 2 (20 mg omeprazole). The tablets (n=6) have been exposed in an artificial gastric juice (pH 1.2) during 2 hours and then analysed for remaining amount of omeprazole (acid resistance). The release of omeprazole was analysed on tablets (n=6) pre-exposed in gastric juice 2 hrs and thereafter exposed in a buffer solution (pH 6.8) during 30 min.
Experiment x-' Enteric coating Acid resistance Release
(% weight per (% residue after (% after 30 min; tablet) 2h; pH 1.2) pH 6.8)
A 8 101 (98-105) 94 (93-96)
B B 8 8 100 (98-102) 95 (85-98)
C 16 98 (96-100)
x' A manufactured in large scale B manufactured in pilot scale C manufactured in laboratory scale
Example 4
Enteric coated pellet formulation containing magnesium omeprazole.
Pellet core
Magnesium omeprazole 225 g
Mannitol 1425 g Hydroxypropyl cellulose 60 g
Microcrystalline cellulose 40 g Lactose anhydrous 80 g
Sodium lauryl sulphate 5 g
Disodium hydrogen phosphate dihydrate 8 g
Water purified 350 g
Subcoating layer (I)
Hydroxypropyl methylcellulose 70 g Water purified 1450 g
Enteric-coating layer (II)
Methacrylic acid copolymer 430 g Polyethylene glycol 40 g
Water purified 1890 g
Polish
Magnesium stearate 5 g
The dry ingredients given above were mixed well in a mixer. Addition of granulation liquid was made and the mixture was kneaded and granulated to a proper consistency. The wet mass was pressed through an extruder and the granules were converted to spherical form in a spheronizer. The pellets were dried and classified into suitable particle size ranges, e.g. 0.5-1.5 mm.
The polymer solution (I) was sprayed on the uncoated pellets in a fluidized bed apparatus under conditions suitable for the equipment used.
The polymer dispersion (II) was sprayed on the subcoated pellets in a fluidized bed apparatus. The enteric -coated pellets were classified, polishing material was admixed and the pellets were filled into hard gelatin capsules in an amount coπesponding to 20 mg of omeprazole, using a capsule filling machine.
Biopharmaceutical tests.
The enteric coated formulations according to Example 2 have been tested in humans with good results.

Claims

1. An oral enteric coated formulation containing a core material of an active substance coated with one or more subcoating layers and one or more enteric coating layers characterized in that the core material as active substance contains a magnesium salt of omeprazole having a degree of crystallinity which is higher than 70 % as determined by X-ray powder diffraction and optionally an alkaline reacting compound, on the core material apphed subcoating layer(s), separating the core material from the enteric coating whereby the thickness of the enteric coating does not essentially influence the release of omeprazole into aqueous solutions at pH values predominantly present in the small intestine.
2. A formulation according to claim 1, wherein the formulation is a tablet formulation.
3. A formulation according to claim 1, wherein the formulation is a pellet formulation.
4. A formulation according to claim 1, wherein the enteric coating comprising an enteric coating material, optionally containing one or more pharmaceutically acceptable plasticizers, dispersants, colorants and pigments.
5. A formulation according to claim 4, wherein the enteric coating comprises water-based polymer solutions or dispersions of acrylates, hydroxypropyl methylcellulose acetate succinate, hydroxypropyl methylcellulose phthalate, polyvinyl acetate phthalate, cellulose acetate trimellitate and/or cellulose acetate phthalate.
6. A formulation according to claim 1, wherein the enteric coating constitutes from 1.0 % by weight of the weight of the' core material.
7. A formulation according to claim 6, wherein the enteric coating constitutes at least 3.0 % by weight of the weight of the core material.
8. A formulation according to claim 1 wherein the subcoating layer(s) comprise polymeric, filmforming compounds or tablet excipients which are soluble or insoluble but disintegrating in water, and optionally containing pH-buffering, alkaline compounds.
9. A formulation according to claim 1 wherein the produced enteric coated formulation contains an overcoat, optionally comprising one or more pharmaceutically acceptable plasticizers, dispersants, colorants and pigments.
10. A process for the manufacture of a formulation according to claim 1 in which the core material containing magnesium omeprazole optionally mixed with an alkaline reacting compound is coated with one or more subcoating layers, whereafter the subcoated core material is further coated with one or more enteric coating layers.
11. A process according to claim 10, wherein the subcoating layer(s) is applied on the core material by a drycoating process.
12. An oral enteric coated formulation according to any of claims 1 to 9 for use in therapy.
13. An oral enteric coated formulation according to any of claims 1 to 9 for use in inhibiting gastric acid secretion in mammals and man.
14. An oral enteric coated formulation according to any of claims 1 to 9 for use in the treatment of gastric acid related diseases in mammals and man.
15. The use of an oral enteric coated formulation according to any of claims 1 to 9 in the manufacture of a medicament for inhibiting gastric acid secretion in mammals and man.
16. The use of an oral enteric coated formulation according to any of claims 1 to 9 in the manufacture of a medicament for treatment of gastric acid related diseases in mammals and man.
17. A method for inhibiting gastric acid secretion in mammals and man by administring to a host in need thereof a therapeutically effective dose of an enteric coated formulation according to any of claims 1 to 9.
18. A method for the treatment of gastric acid related diseases in mammals and man by administring to a host in need thereof a therapeutically effective dose of an enteric coated formulation according to any of claims 1 to 9.
PCT/SE1994/000681 1993-07-09 1994-07-08 New pharmaceutical formulation WO1995001783A1 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
HU9503874A HU226779B1 (en) 1993-07-09 1994-07-08 Pharmaceutical formulation a novel physical form of the magnesium salt of omeprazole
AU71982/94A AU681686B2 (en) 1993-07-09 1994-07-08 New pharmaceutical formulation
US08/313,036 US5690960A (en) 1993-07-09 1994-07-08 Pharmaceutical formulation of omeprazole
UA96010058A UA43342C2 (en) 1993-07-09 1994-07-08 Pharmaceutical composition with the enterosoluble coating for the oral administration, method of obtaining thereof, method for inhibition secretion of acid by stomach in mammals and human, method of treating the diseases in mammals and human, associated with the secretion of acid with the stomach
DK94921155T DK0706378T3 (en) 1993-07-09 1994-07-08 New pharmaceutical formulation.
SI9430438T SI0706378T1 (en) 1993-07-09 1994-07-08 New pharmaceutical formulation
RU96102154/14A RU2138254C9 (en) 1993-07-09 1994-07-08 Pharmaceutical composition with enterosoluble coating, method of its preparing, method of treatment of patients
JP50400695A JP3665334B2 (en) 1993-07-09 1994-07-08 New pharmaceutical formulation
BR9406941A BR9406941A (en) 1993-07-09 1994-07-08 Oral formulation with enteric coating process for the preparation of the formulation process for the inhibition of gastric acid secretion in mammals and in man and process for the treatment of diseases related to gastric acid in mammals and in man
SK21-96A SK281105B6 (en) 1993-07-09 1994-07-08 Enteric coated, stable oral formulation, method for the production thereof and use of such formulation
DE69432076T DE69432076T2 (en) 1993-07-09 1994-07-08 NEW PHARMACEUTICAL FORMULATIONS
KR1019960700052A KR100350203B1 (en) 1993-07-09 1994-07-08 New Pharmaceutical Formulation of Omeprazole
PL94312441A PL175210B1 (en) 1993-07-09 1994-07-08 New pharmaceutical compositions
AT94921155T ATE231719T1 (en) 1993-07-09 1994-07-08 NEW PHARMACEUTICAL FORMULATIONS
EP94921155A EP0706378B1 (en) 1993-07-09 1994-07-08 New pharmaceutical formulation
NO19960067A NO315146B1 (en) 1993-07-09 1996-01-05 Oral enteric coated formulation, process for its preparation, and use thereof
FI960102A FI114008B (en) 1993-07-09 1996-01-09 A process for the preparation of an oral enteric coating formulation
HK98109229A HK1008299A1 (en) 1993-07-09 1998-07-17 New pharmaceutical formulation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9302395-0 1993-07-09
SE19939302395A SE9302395D0 (en) 1993-07-09 1993-07-09 NEW PHARMACEUTICAL FORMULATION

Publications (1)

Publication Number Publication Date
WO1995001783A1 true WO1995001783A1 (en) 1995-01-19

Family

ID=20390587

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE1994/000681 WO1995001783A1 (en) 1993-07-09 1994-07-08 New pharmaceutical formulation

Country Status (40)

Country Link
US (1) US5690960A (en)
EP (1) EP0706378B1 (en)
JP (1) JP3665334B2 (en)
KR (1) KR100350203B1 (en)
CN (1) CN1126946A (en)
AT (1) ATE231719T1 (en)
AU (1) AU681686B2 (en)
BR (1) BR9406941A (en)
CA (1) CA2166483C (en)
CZ (1) CZ290323B6 (en)
DE (1) DE69432076T2 (en)
DK (1) DK0706378T3 (en)
DZ (1) DZ1794A1 (en)
EE (1) EE03148B1 (en)
EG (1) EG22373A (en)
ES (1) ES2191682T3 (en)
FI (1) FI114008B (en)
HK (1) HK1008299A1 (en)
HR (1) HRP940386B1 (en)
HU (1) HU226779B1 (en)
IL (1) IL110189A0 (en)
IS (1) IS2034B (en)
LV (1) LV13140B (en)
MA (1) MA23258A1 (en)
MX (1) MX9405219A (en)
MY (1) MY128809A (en)
NO (1) NO315146B1 (en)
NZ (1) NZ268694A (en)
PL (1) PL175210B1 (en)
RU (1) RU2138254C9 (en)
SA (1) SA94150057B1 (en)
SE (1) SE9302395D0 (en)
SG (1) SG52365A1 (en)
SI (1) SI0706378T1 (en)
SK (1) SK281105B6 (en)
TN (1) TNSN94078A1 (en)
UA (1) UA43342C2 (en)
WO (1) WO1995001783A1 (en)
YU (1) YU49199B (en)
ZA (1) ZA944934B (en)

Cited By (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996001622A1 (en) * 1994-07-08 1996-01-25 Astra Aktiebolag New oral pharmaceutical formulation containing magnesium salt of omeprazole
US5690960A (en) * 1993-07-09 1997-11-25 Astra Aktiebolag Pharmaceutical formulation of omeprazole
WO1998000114A2 (en) * 1996-06-28 1998-01-08 Klinge Pharma Gmbh Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
US5753265A (en) * 1994-07-08 1998-05-19 Astra Aktiebolag Multiple unit pharmaceutical preparation
US5817338A (en) * 1994-07-08 1998-10-06 Astra Aktiebolag Multiple unit tableted dosage form of omeprazole
WO1998050019A1 (en) * 1997-05-09 1998-11-12 Sage Pharmaceuticals, Inc. Stable oral pharmaceutical dosage forms
JPH11501951A (en) * 1996-01-08 1999-02-16 アストラ・アクチエボラーグ Multiple unit boiling dosage forms containing proton pump inhibitors.
JPH11502848A (en) * 1995-03-24 1999-03-09 イーライ・リリー・アンド・カンパニー Oral 2-methyl-thieno-benzodiazepine preparation
WO1999027917A1 (en) * 1997-11-28 1999-06-10 Byk Gulden Lomberg Chemische Fabrik Gmbh Medicament preparation in the form of a tablet or pellet for acid-labile active substances
US6077541A (en) * 1997-11-14 2000-06-20 Andrx Pharmaceuticals, Inc. Omeprazole formulation
WO2000078293A1 (en) * 1999-06-22 2000-12-28 Astrazeneca Ab New formulation
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
JP2001501207A (en) * 1996-09-24 2001-01-30 イーライ・リリー・アンド・カンパニー Coated particle formulation
US6316020B1 (en) * 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
US6403616B1 (en) 1998-11-18 2002-06-11 Astrazeneca Ab Chemical process and pharmaceutical formulation
EP1213015A1 (en) * 1995-07-05 2002-06-12 Byk Gulden Lomberg Chemische Fabrik GmbH Oral pharmaceutical composition with delayed release of proton pump inhibitors
US6576258B1 (en) 1997-07-14 2003-06-10 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Pharmaceutical formulation with controlled release of active substances
US6610323B1 (en) 1997-12-22 2003-08-26 Astrazeneca Ab Oral pharmaceutical pulsed release dosage form
ES2191521A1 (en) * 2000-11-22 2003-09-01 Belmac S A Lab Galenical formula for omeprazole tablets comprises nucleus including omeprazole, insulating cover and gastro-resistant cover
US6623759B2 (en) 1996-06-28 2003-09-23 Astrazeneca Ab Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
WO2003077829A2 (en) * 2002-03-08 2003-09-25 Modi, Rajiv, Indravadan Process for preparation of a pharmaceutical composition containing acid labile compounds
US6733778B1 (en) 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
WO2004062695A1 (en) * 2003-01-10 2004-07-29 Nature Vet Orally deliverable pharmaceutical composition containing protein pump inhibitors
US6780882B2 (en) 1996-01-04 2004-08-24 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
EP1459737A1 (en) * 2001-10-17 2004-09-22 Takeda Chemical Industries, Ltd. Granules containing acid-unstable chemical in large amount
EP1462097A1 (en) * 2003-03-28 2004-09-29 Acme Drugs S.r.l. Process for the preparation of enteric-coated and /or controlled-release medicaments containing active principles sensitive to gastrointestinal environment
US6875872B1 (en) 1993-05-28 2005-04-05 Astrazeneca Compounds
WO2005082888A1 (en) * 2004-03-01 2005-09-09 Milen Merkez Ilac Endustrisi A.S. Process for the preparation of magnesium salt of omeprazole
EP1660043A2 (en) * 2003-07-23 2006-05-31 The Curators of the University of Missouri Immediate-release formulation of acid-labile pharmaceutical compositions
US7094426B2 (en) * 1998-08-27 2006-08-22 Sage Pharmaceuticals, Inc. Stable oral pharmaceutical dosage forms
US8722084B2 (en) 2002-10-16 2014-05-13 Takeda Pharmaceutical Company Limited Controlled release preparation
USRE45198E1 (en) 1996-01-04 2014-10-14 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US9238029B2 (en) 2004-06-16 2016-01-19 Takeda Pharmaceuticals U.S.A., Inc. Multiple PPI dosage form
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
WO2018219369A1 (en) 2017-06-02 2018-12-06 Zentiva, K.S. A dosage unit with ppis (proton pump inhibitors)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9301830D0 (en) * 1993-05-28 1993-05-28 Ab Astra NEW COMPOUNDS
SE9500478D0 (en) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
US6699885B2 (en) 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
SE508669C2 (en) * 1996-04-26 1998-10-26 Astra Ab New procedure
TW385306B (en) * 1996-11-14 2000-03-21 Takeda Chemical Industries Ltd Method for producing crystals of benzimidazole derivatives
SE9702000D0 (en) * 1997-05-28 1997-05-28 Astra Ab New pharmaceutical formulation
US6747155B2 (en) 1997-05-30 2004-06-08 Astrazeneca Ab Process
SE510650C2 (en) * 1997-05-30 1999-06-14 Astra Ab New association
US20050244497A1 (en) * 1997-11-05 2005-11-03 Wockhardt Limited Delayed delivery system for acid-sensitive drugs
ATE526022T1 (en) * 1998-04-20 2011-10-15 Eisai R&D Man Co Ltd STABILIZED COMPOSITIONS CONTAINING BENZIMIDAZOLES
UA73092C2 (en) * 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Tablets with enteric coating and method for their manufacture
SE9803772D0 (en) * 1998-11-05 1998-11-05 Astra Ab Pharmaceutical formulation
IL142703A (en) * 1998-11-10 2006-04-10 Astrazeneca Ab Crystalline form of omeprazole
UA72748C2 (en) * 1998-11-10 2005-04-15 Astrazeneca Ab A novel crystalline form of omeprazole
US6365128B1 (en) * 1998-12-18 2002-04-02 Medical Defence Technologies, Llc Monitoring gastrointestinal function to guide care of high risk patients
EP1244430A4 (en) * 1999-03-29 2004-01-14 Wyeth Corp Coating system
IL130602A0 (en) * 1999-06-22 2000-06-01 Dexcel Ltd Stable benzimidazole formulation
US6245913B1 (en) 1999-06-30 2001-06-12 Wockhardt Europe Limited Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
US6500459B1 (en) * 1999-07-21 2002-12-31 Harinderpal Chhabra Controlled onset and sustained release dosage forms and the preparation thereof
DK1222922T3 (en) 1999-10-20 2007-12-03 Eisai R&D Man Co Ltd Process for Stabilizing Benzimidazole Compounds
WO2001087831A2 (en) * 2000-05-15 2001-11-22 Ranbaxy Laboratories Limited Novel amorphous form of omeprazole salts
US20030070584A1 (en) 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
US8309118B2 (en) 2001-09-28 2012-11-13 Mcneil-Ppc, Inc. Film forming compositions containing sucralose
JP2005521662A (en) * 2002-01-25 2005-07-21 サンタラス インコーポレイティッド Transmucosal delivery of proton pump inhibitors
DE60319707T2 (en) * 2002-08-02 2008-07-17 Ratiopharm Gmbh PHARMACEUTICAL COMPOSITION CONTAINING A BENZIMIDAZOLE DERIVATIVE MIXED WITH MICROCRYSTALLINE CELLULOSE
US7429619B2 (en) 2002-08-02 2008-09-30 Mcneil Consumer Healthcare Polyacrylic film forming compositions
EP1660052A2 (en) * 2003-09-03 2006-05-31 Agi Therapeutics Limited Proton pump inhibitor formulations, and methods of preparing and using such formulations
US20050214388A1 (en) * 2004-02-18 2005-09-29 Gorham Thomas R Multivitamin formulations containing controlled-release magnesium
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20060024362A1 (en) * 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
CN101111233A (en) 2004-12-23 2008-01-23 兰贝克赛实验室有限公司 Stable oral benzimidazole compositions and process of preparation thereof
US20080279951A1 (en) * 2005-02-02 2008-11-13 Rajesh Gandhi Stable Oral Benzimidazole Compositions Prepared by Non-Aqueous Layering Process
CA2599340C (en) 2005-02-25 2012-12-04 Takeda Pharmaceutical Company Limited Method for producing granules
EP1934201A1 (en) * 2005-10-06 2008-06-25 Auspex Pharmaceuticals Inc. Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
JP2009538901A (en) * 2006-06-01 2009-11-12 デクセル ファーマ テクノロジーズ エルティーディー． Dual unit pharmaceutical formulation
US20090252787A1 (en) * 2006-07-28 2009-10-08 Dr. Reddy's Laboratories Ltd. Granular pharmaceutical compositions
CA2665226C (en) 2006-10-05 2014-05-13 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
EP2486910A3 (en) 2006-10-27 2012-08-22 The Curators Of The University Of Missouri Multi-chambered apparatus comprising a dispenser head
US20080194307A1 (en) * 2007-02-13 2008-08-14 Jeff Sanger Sports-based game of chance
WO2009113090A2 (en) * 2008-01-17 2009-09-17 Alkem Laboratories Ltd. Process for preparing an oral formulation of an acid-sensitive benzimidazole drug
US8247440B2 (en) 2008-02-20 2012-08-21 Curators Of The University Of Missouri Composition comprising omeprazole, lansoprazole and at least one buffering agent
US8911787B2 (en) 2008-02-26 2014-12-16 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and process of preparation thereof
EP2293782B1 (en) * 2008-05-06 2015-08-12 Dexcel Pharma Technologies Ltd. Stable benzimidazole formulation
WO2009137648A1 (en) * 2008-05-09 2009-11-12 Aptapharma, Inc. Multilayer proton pump inhibitor tablets
EP2344139A1 (en) 2008-09-09 2011-07-20 AstraZeneca AB Method for delivering a pharmaceutical composition to patient in need thereof
UA125896C2 (en) 2009-01-09 2022-07-06 Фвп Іп Апс PHARMACEUTICAL COMPOSITION CONTAINING ONE OR MORE FUMARIC ACID ESTERS IN AN Erodible MATRIX
JP2012531409A (en) 2009-06-25 2012-12-10 アストラゼネカ・アクチエボラーグ Methods for treating patients at risk of developing NSAID-related ulcers
EP2345408A3 (en) 2010-01-08 2012-02-29 Dr. Reddy's Laboratories Ltd. Acid labile drug formulations
WO2012174102A2 (en) 2011-06-14 2012-12-20 Medical Defense Technologies, Llc. Methods and apparatus for guiding medical care based on detected gastric function
EA028049B1 (en) 2011-12-28 2017-10-31 Поузен Инк. Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
CN103127026B (en) * 2013-02-05 2017-02-15 悦康药业集团有限公司 Omeprazole enteric capsule and prepared method thereof
CN103735526A (en) * 2013-08-08 2014-04-23 上海海虹实业(集团)巢湖今辰药业有限公司 Omeprazole magnesium enteric-coated tablet and manufacturing method thereof
CN103467453A (en) * 2013-09-13 2013-12-25 上海海虹实业(集团)巢湖今辰药业有限公司 Preparation method of omeprazole magnesium crude medicine
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10736855B2 (en) 2016-02-25 2020-08-11 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
JPWO2021153525A1 (en) 2020-01-27 2021-08-05
US11426353B2 (en) * 2020-06-24 2022-08-30 13400719 Canada Inc. Composite coating for an active agent
CN113350313B (en) * 2021-06-23 2023-08-11 福建金山生物制药股份有限公司 Esomeprazole magnesium sustained-release preparation and preparation method thereof
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0124495A2 (en) * 1983-03-04 1984-11-07 Aktiebolaget Hässle Omeprazole salts
EP0247983A2 (en) * 1986-04-30 1987-12-02 Aktiebolaget Hässle New pharmaceutical preparation for oral use
EP0342522A1 (en) * 1988-05-18 1989-11-23 Eisai Co., Ltd. Peroral preparation of an acid-unstable compound

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (en) * 1978-04-14 1979-10-15 Haessle Ab Gastric acid secretion
SE9302396D0 (en) * 1993-07-09 1993-07-09 Ab Astra A NOVEL COMPOUND FORM
SE9302395D0 (en) * 1993-07-09 1993-07-09 Ab Astra NEW PHARMACEUTICAL FORMULATION

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0124495A2 (en) * 1983-03-04 1984-11-07 Aktiebolaget Hässle Omeprazole salts
EP0247983A2 (en) * 1986-04-30 1987-12-02 Aktiebolaget Hässle New pharmaceutical preparation for oral use
EP0342522A1 (en) * 1988-05-18 1989-11-23 Eisai Co., Ltd. Peroral preparation of an acid-unstable compound

Cited By (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6875872B1 (en) 1993-05-28 2005-04-05 Astrazeneca Compounds
US5690960A (en) * 1993-07-09 1997-11-25 Astra Aktiebolag Pharmaceutical formulation of omeprazole
US5753265A (en) * 1994-07-08 1998-05-19 Astra Aktiebolag Multiple unit pharmaceutical preparation
US5817338A (en) * 1994-07-08 1998-10-06 Astra Aktiebolag Multiple unit tableted dosage form of omeprazole
WO1996001622A1 (en) * 1994-07-08 1996-01-25 Astra Aktiebolag New oral pharmaceutical formulation containing magnesium salt of omeprazole
JPH11502848A (en) * 1995-03-24 1999-03-09 イーライ・リリー・アンド・カンパニー Oral 2-methyl-thieno-benzodiazepine preparation
EP1213015A1 (en) * 1995-07-05 2002-06-12 Byk Gulden Lomberg Chemische Fabrik GmbH Oral pharmaceutical composition with delayed release of proton pump inhibitors
USRE45198E1 (en) 1996-01-04 2014-10-14 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6780882B2 (en) 1996-01-04 2004-08-24 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
JPH11501951A (en) * 1996-01-08 1999-02-16 アストラ・アクチエボラーグ Multiple unit boiling dosage forms containing proton pump inhibitors.
JP4638561B2 (en) * 1996-01-08 2011-02-23 アストラゼネカ・アクチエボラーグ Multiple unit boiling dosage forms containing proton pump inhibitors
US6623759B2 (en) 1996-06-28 2003-09-23 Astrazeneca Ab Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
US7276253B2 (en) 1996-06-28 2007-10-02 Astrazeneca Ab Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
WO1998000114A2 (en) * 1996-06-28 1998-01-08 Klinge Pharma Gmbh Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
WO1998000114A3 (en) * 1996-06-28 1998-02-26 Klinge Co Chem Pharm Fab Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
JP2000514051A (en) * 1996-06-28 2000-10-24 クリンゲ ファーマ ジーエムビーエイチ Stable pharmaceutical form for oral administration containing benzimidazole derivative as active ingredient and method for producing the same
JP4641075B2 (en) * 1996-06-28 2011-03-02 アストラゼネカ・アクチエボラーグ Stable pharmaceutical form for oral administration containing benzimidazole derivative as active ingredient and method for producing the same
JP2001501207A (en) * 1996-09-24 2001-01-30 イーライ・リリー・アンド・カンパニー Coated particle formulation
WO1998050019A1 (en) * 1997-05-09 1998-11-12 Sage Pharmaceuticals, Inc. Stable oral pharmaceutical dosage forms
US7041316B2 (en) * 1997-05-09 2006-05-09 Sage Pharmaceuticals, Inc. Stable oral pharmaceutical dosage forms
US6726927B2 (en) 1997-05-09 2004-04-27 Sage Pharmaceuticals, Inc. Preparation of enteric pharmaceutical dosage forms for omerprazole and lansoprazole
US6576258B1 (en) 1997-07-14 2003-06-10 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Pharmaceutical formulation with controlled release of active substances
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6077541A (en) * 1997-11-14 2000-06-20 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6780435B2 (en) 1997-11-14 2004-08-24 Andrx Pharmaceuticals, Inc. Omeprazole formulation
WO1999027917A1 (en) * 1997-11-28 1999-06-10 Byk Gulden Lomberg Chemische Fabrik Gmbh Medicament preparation in the form of a tablet or pellet for acid-labile active substances
US6610323B1 (en) 1997-12-22 2003-08-26 Astrazeneca Ab Oral pharmaceutical pulsed release dosage form
US7094426B2 (en) * 1998-08-27 2006-08-22 Sage Pharmaceuticals, Inc. Stable oral pharmaceutical dosage forms
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6855336B2 (en) 1998-08-28 2005-02-15 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6403616B1 (en) 1998-11-18 2002-06-11 Astrazeneca Ab Chemical process and pharmaceutical formulation
WO2000078293A1 (en) * 1999-06-22 2000-12-28 Astrazeneca Ab New formulation
US6316020B1 (en) * 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
US6733778B1 (en) 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
ES2191521A1 (en) * 2000-11-22 2003-09-01 Belmac S A Lab Galenical formula for omeprazole tablets comprises nucleus including omeprazole, insulating cover and gastro-resistant cover
EP1459737A4 (en) * 2001-10-17 2007-09-26 Takeda Pharmaceutical Granules containing acid-unstable chemical in large amount
EP1459737A1 (en) * 2001-10-17 2004-09-22 Takeda Chemical Industries, Ltd. Granules containing acid-unstable chemical in large amount
US8105626B2 (en) 2001-10-17 2012-01-31 Takeda Pharmaceutical Company Limited Granules containing acid-unstable chemical in large amount
WO2003077829A3 (en) * 2002-03-08 2003-12-04 Bakulesh Mafatlal Khamar Process for preparation of a pharmaceutical composition containing acid labile compounds
WO2003077829A2 (en) * 2002-03-08 2003-09-25 Modi, Rajiv, Indravadan Process for preparation of a pharmaceutical composition containing acid labile compounds
US8722084B2 (en) 2002-10-16 2014-05-13 Takeda Pharmaceutical Company Limited Controlled release preparation
US8784885B2 (en) 2002-10-16 2014-07-22 Takeda Pharmaceutical Company Limited Controlled release preparation
WO2004062695A1 (en) * 2003-01-10 2004-07-29 Nature Vet Orally deliverable pharmaceutical composition containing protein pump inhibitors
EP1462097A1 (en) * 2003-03-28 2004-09-29 Acme Drugs S.r.l. Process for the preparation of enteric-coated and /or controlled-release medicaments containing active principles sensitive to gastrointestinal environment
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
EP1660043A4 (en) * 2003-07-23 2012-07-04 Univ Missouri Immediate-release formulation of acid-labile pharmaceutical compositions
EP1660043A2 (en) * 2003-07-23 2006-05-31 The Curators of the University of Missouri Immediate-release formulation of acid-labile pharmaceutical compositions
WO2005082888A1 (en) * 2004-03-01 2005-09-09 Milen Merkez Ilac Endustrisi A.S. Process for the preparation of magnesium salt of omeprazole
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US9238029B2 (en) 2004-06-16 2016-01-19 Takeda Pharmaceuticals U.S.A., Inc. Multiple PPI dosage form
US9889152B2 (en) 2004-06-16 2018-02-13 Takeda Pharmaceuticals U.S.A., Inc. Multiple PPI dosage form
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US10835488B2 (en) 2016-06-16 2020-11-17 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
WO2018219369A1 (en) 2017-06-02 2018-12-06 Zentiva, K.S. A dosage unit with ppis (proton pump inhibitors)

Also Published As

Publication number Publication date
AU681686B2 (en) 1997-09-04
DE69432076D1 (en) 2003-03-06
RU2138254C1 (en) 1999-09-27
YU43794A (en) 1997-07-31
SG52365A1 (en) 1998-09-28
HRP940386B1 (en) 2003-10-31
PL175210B1 (en) 1998-11-30
CA2166483C (en) 1997-09-16
LV13140B (en) 2004-08-20
NO960067L (en) 1996-01-05
DE69432076T2 (en) 2003-10-16
ZA944934B (en) 1995-02-20
HRP940386A2 (en) 1997-02-28
FI960102A (en) 1996-01-09
EP0706378B1 (en) 2003-01-29
HK1008299A1 (en) 1999-05-07
JP3665334B2 (en) 2005-06-29
AU7198294A (en) 1995-02-06
CZ7096A3 (en) 1996-06-12
EG22373A (en) 2002-12-31
SA94150057B1 (en) 2006-10-03
SE9302395D0 (en) 1993-07-09
MY128809A (en) 2007-02-28
UA43342C2 (en) 2001-12-17
FI960102A0 (en) 1996-01-09
NO315146B1 (en) 2003-07-21
IS2034B (en) 2005-08-15
YU49199B (en) 2004-09-03
BR9406941A (en) 1996-09-10
HU9503874D0 (en) 1996-02-28
JPH08512316A (en) 1996-12-24
NO960067D0 (en) 1996-01-05
CA2166483A1 (en) 1995-01-19
RU2138254C9 (en) 2009-09-27
NZ268694A (en) 1997-05-26
US5690960A (en) 1997-11-25
SK281105B6 (en) 2000-12-11
PL312441A1 (en) 1996-04-29
HUT75306A (en) 1997-05-28
SK2196A3 (en) 1997-04-09
EE03148B1 (en) 1999-02-15
ATE231719T1 (en) 2003-02-15
MA23258A1 (en) 1995-04-01
SI0706378T1 (en) 2003-06-30
IL110189A0 (en) 1994-10-21
IS4187A (en) 1995-01-10
EP0706378A1 (en) 1996-04-17
ES2191682T3 (en) 2003-09-16
CN1126946A (en) 1996-07-17
DZ1794A1 (en) 2002-02-17
HU226779B1 (en) 2009-10-28
FI114008B (en) 2004-07-30
KR100350203B1 (en) 2002-12-28
TNSN94078A1 (en) 1995-04-25
DK0706378T3 (en) 2003-05-05
CZ290323B6 (en) 2002-07-17
MX9405219A (en) 1995-01-31

Similar Documents

Publication Publication Date Title
AU681686B2 (en) New pharmaceutical formulation
RU2095054C1 (en) Solid medicinal formula for oral administration
DK169987B1 (en) Orally administrable pharmaceutical composition containing as an active ingredient an acid labile compound or an alkali salt thereof, and a process for the preparation of the composition
CA2290531C (en) Pharmaceutical formulation of omeprazole
AU774278B2 (en) Pharmaceutical formulation comprising omeprazole
JPH09502739A (en) Multiple unit tableted dosage form ▲ I ▼
WO1996001622A1 (en) New oral pharmaceutical formulation containing magnesium salt of omeprazole
AU695723C (en) New oral pharmaceutical formulation containing magnesium salt of omeprazole
RU2173995C2 (en) Medicinal preparation for oral administration containing omeprazole magnesium salt
JPH10504288A (en) Novel oral pharmaceutical formulations containing magnesium salt of omeprazole

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 94192734.2

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 08313036

Country of ref document: US

AK Designated states

Kind code of ref document: A1

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KE KG KP KR KZ LK LT LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE MW SD AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1994921155

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2166483

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2196

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: 268694

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 960102

Country of ref document: FI

Ref document number: PV1996-70

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1994921155

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV1996-70

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: PV1996-70

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 1994921155

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 960102

Country of ref document: FI